Key result
Aspirin initiation in CKD without prior CVD shows no link to reduced major cardiovascular events.
Why the study?
Despite high cardiovascular risk in patients with CKD, the role of aspirin in primary prevention remains unclear.
Does aspirin initiation reduce the risk of nonfatal atherosclerotic CVD or cardiovascular death in adults with CKD without prior CVD?
Cohort (n=95,166)
Yes
Does aspirin initiation reduce the risk of nonfatal atherosclerotic CVD or cardiovascular death in adults with CKD without prior CVD?
Effect estimate: HR 0.93 (95% CI 0.86-1.04)
Absolute Event Rate: 8% vs 9%
In patients with CKD stages G3 and G4 without prior CVD, aspirin initiation for primary prevention does not reduce cardiovascular events but significantly increases the risk of major bleeding.
No CVD benefit seen with aspirin for primary prevention in CKD; leaves open need for RCTs to confirm net harm.
Key Points The association between aspirin use and risk of the first cardiovascular event was NS in patients with CKD. Compared with nonusers, aspirin users had an increased risk of significant bleeding events. Aspirin prescription for the primary prevention of cardiovascular disease in patients with CKD needs careful consideration. Background Despite the high cardiovascular risk in patients with CKD, the role of aspirin in primary prevention remains unclear. This study aimed to investigate the association between aspirin initiation in adults with CKD without prior cardiovascular disease (CVD) and the first cardiovascular and bleeding events using Korean nationwide cohort data. Methods Among individuals aged 40–79 years with an eGFR between 15 and 59 ml/min per 1.73 m 2 who underwent routine health examinations between 2011 and 2016, 15,861 individuals who were newly prescribed aspirin at a dose of 100 mg/d were matched with 79,305 aspirin non-users by propensity score matching. The primary efficacy outcome was a composite of nonfatal atherosclerotic CVD or cardiovascular death. The primary safety outcome was hospitalization due to intracranial or gastrointestinal bleeding. Results During a mean follow-up of 6.9±2.9 years, the incidence rates for the primary efficacy outcome in aspirin users and nonusers were 8.0 and 9.0 per 1000 person-years, respectively. Aspirin therapy initiation was not associated with the primary efficacy outcome (hazard ratio, 0.93; 95% confidence intervals, 0.86 to 1.04). However, the primary safety outcome of major bleeding was more frequent in aspirin users than in nonusers (6.7 versus 4.7 per 1000 person-years). The hazard ratio for this outcome in aspirin users versus nonusers was 1.45 (95% confidence intervals, 1.32 to 1.59). Conclusions No association was observed between aspirin use and the risk of nonfatal atherosclerotic CVD or cardiovascular death in patients with CKD stages G3 and G4 without prior CVD. Aspirin use was associated with higher risk of major bleeding.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2024) conducted a cohort in Chronic Kidney Disease without prior cardiovascular disease (n=95,166). Aspirin vs. Aspirin non-users was evaluated on Composite of nonfatal atherosclerotic CVD or cardiovascular death (HR 0.93, 95% CI 0.86-1.04). Aspirin initiation in patients with CKD without prior CVD was not associated with a reduced risk of nonfatal atherosclerotic CVD or cardiovascular death (HR 0.93; 95% CI 0.86-1.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: